Index RUT P/E - EPS (ttm) -0.63 Insider Own 19.19% Shs Outstand 116.86M Perf Week -1.35%
Market Cap 514.20M Forward P/E - EPS next Y -0.41 Insider Trans 1.81% Shs Float 94.64M Perf Month -0.90%
Income -63.48M PEG - EPS next Q -0.17 Inst Own 59.31% Short Float 5.89% Perf Quarter -23.39%
Sales 21.05M P/S 24.43 EPS this Y -24.02% Inst Trans 0.72% Short Ratio 10.18 Perf Half Y -0.23%
Book/sh 2.57 P/B 1.71 EPS next Y 35.18% ROA -16.58% Short Interest 5.58M Perf Year 2.33%
Cash/sh 0.59 P/C 7.45 EPS next 5Y - ROE -19.77% 52W Range 4.10 - 6.72 Perf YTD -28.85%
Dividend Est. - P/FCF - EPS past 5Y - ROI -19.66% 52W High -34.62% Beta -0.06
Dividend TTM - Quick Ratio 4.38 Sales past 5Y 13.92% Gross Margin 6.93% 52W Low 7.07% ATR (14) 0.17
Dividend Ex-Date - Current Ratio 4.38 EPS Y/Y TTM -384.71% Oper. Margin -395.91% RSI (14) 40.63 Volatility 3.25% 3.53%
Employees 106 Debt/Eq 0.08 Sales Y/Y TTM -59.73% Profit Margin -301.63% Recom 1.00 Target Price 9.88
Option/Short Yes / Yes LT Debt/Eq 0.07 EPS Q/Q -206.02% Payout - Rel Volume 1.13 Prev Close 4.29
Sales Surprise -35.24% EPS Surprise -17.79% Sales Q/Q -77.53% Earnings May 09 AMC Avg Volume 547.43K Price 4.39
SMA20 -2.77% SMA50 -9.78% SMA200 -16.28% Trades
Volume 619,702 Change 2.33%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-29-23 Initiated RBC Capital Mkts
Outperform
$6
Apr-21-23 Initiated The Benchmark Company
Buy
$8
Apr-13-23 Initiated Craig Hallum
Buy
$10
Feb-22-23 Initiated Cowen
Outperform
$10
Feb-13-23 Initiated H.C. Wainwright
Buy
$11
Dec-20-22 Initiated Truist
Buy
$10
Dec-16-22 Initiated Credit Suisse
Outperform
$13
Nov-29-22 Initiated SVB Leerink
Outperform
$6
Nov-28-22 Initiated Stifel
Buy
$12
May-20-24 08:05AM
May-15-24 04:05PM
May-12-24 03:24PM
May-09-24 08:56PM
04:05PM
08:00AM
Loading…
May-01-24 08:00AM
Apr-22-24 08:00AM
Mar-21-24 11:31AM
Mar-20-24 08:54PM
04:05PM
Feb-28-24 08:27AM
Feb-26-24 08:00AM
Feb-20-24 08:00AM
Dec-14-23 04:30PM
Nov-20-23 12:39PM
05:03AM
Loading…
Nov-14-23 05:03AM
Nov-09-23 05:55PM
09:24AM
08:00AM
Nov-02-23 08:00AM
Nov-01-23 09:00AM
Oct-31-23 04:28PM
Oct-26-23 02:32PM
Oct-12-23 08:00AM
Sep-05-23 08:00AM
Aug-15-23 05:20AM
Aug-13-23 08:06AM
Aug-10-23 04:05PM
Aug-07-23 04:05PM
Jul-31-23 08:00AM
07:35AM
Loading…
Jul-17-23 07:35AM
Jun-13-23 06:00AM
May-18-23 05:09PM
May-17-23 04:05PM
May-16-23 06:06AM
May-14-23 08:03AM
May-11-23 10:55PM
(Thomson Reuters StreetEvents)
07:00AM
May-05-23 07:14AM
May-04-23 06:26AM
May-01-23 08:00AM
Apr-26-23 08:01PM
Apr-25-23 08:00AM
Apr-19-23 08:30AM
Apr-07-23 10:24PM
Apr-05-23 06:09AM
Apr-02-23 08:51AM
Mar-31-23 08:40AM
Mar-30-23 04:05PM
Mar-15-23 11:44AM
Mar-09-23 08:00AM
Mar-08-23 09:53AM
Feb-23-23 07:49AM
Feb-07-23 08:00AM
Feb-01-23 06:56AM
Dec-16-22 12:39PM
Dec-01-22 08:47AM
Nov-15-22 07:00AM
Nov-03-22 08:00AM
Nov-02-22 07:00AM
Nov-01-22 04:01PM
04:01PM
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GUSTAFSON KURT A Executive VP, Finance and CFO Apr 08 '24 Sale 5.27 6,954 36,648 176,697 Apr 09 06:38 PM Berkman Charles S Chief Legal Officer Apr 08 '24 Sale 5.27 6,954 36,648 292,617 Apr 09 06:37 PM GUSTAFSON KURT A Executive VP, Finance & CFO Apr 01 '24 Sale 5.46 11,849 64,696 170,110 Apr 02 06:30 PM FOEHR MATTHEW W President and CEO Mar 27 '24 Option Exercise 3.72 243,613 907,023 3,152,416 Mar 29 04:52 PM FOEHR MATTHEW W President and CEO Mar 22 '24 Buy 5.19 225,000 1,167,750 2,908,803 Mar 25 07:07 AM FOEHR MATTHEW W Chief Executive Officer Dec 12 '23 Buy 5.05 200,000 1,010,000 2,645,442 Dec 13 03:25 PM FOEHR MATTHEW W President and CEO Nov 10 '23 Buy 4.27 95,000 405,517 2,427,919 Nov 13 08:00 AM FOEHR MATTHEW W President and CEO Aug 14 '23 Buy 5.48 45,000 246,600 2,332,919 Aug 15 04:56 PM FOEHR MATTHEW W Chief Executive Officer Jun 09 '23 Buy 4.52 115,000 519,800 2,574,009 Jun 12 04:47 PM
Index RUT P/E 16.24 EPS (ttm) 5.32 Insider Own 2.46% Shs Outstand 17.56M Perf Week 0.40%
Market Cap 1.55B Forward P/E 15.59 EPS next Y 5.54 Insider Trans -9.03% Shs Float 17.52M Perf Month 22.78%
Income 96.34M PEG 0.81 EPS next Q 0.99 Inst Own 93.50% Short Float 4.90% Perf Quarter 16.10%
Sales 118.31M P/S 13.12 EPS this Y -23.81% Inst Trans -0.32% Short Ratio 4.55 Perf Half Y 45.19%
Book/sh 45.00 P/B 1.92 EPS next Y 19.47% ROA 11.17% Short Interest 0.86M Perf Year 15.83%
Cash/sh 17.29 P/C 5.00 EPS next 5Y 20.00% ROE 13.26% 52W Range 49.24 - 94.57 Perf YTD 20.97%
Dividend Est. - P/FCF 48.25 EPS past 5Y -13.18% ROI 11.87% 52W High -8.64% Beta 1.04
Dividend TTM - Quick Ratio 19.51 Sales past 5Y -3.89% Gross Margin 64.12% 52W Low 75.47% ATR (14) 2.70
Dividend Ex-Date Jul 02, 2010 Current Ratio 20.70 EPS Y/Y TTM 290.26% Oper. Margin -1.18% RSI (14) 63.76 Volatility 2.61% 3.47%
Employees 58 Debt/Eq 0.01 Sales Y/Y TTM -45.70% Profit Margin 81.43% Recom 1.20 Target Price 116.80
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q 103.66% Payout 0.00% Rel Volume 0.85 Prev Close 84.91
Sales Surprise 10.94% EPS Surprise 43.88% Sales Q/Q -29.56% Earnings May 07 AMC Avg Volume 188.58K Price 86.40
SMA20 7.97% SMA50 12.72% SMA200 26.72% Trades
Volume 160,609 Change 1.75%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-14-21 Resumed Stephens
Overweight
$200
Feb-04-21 Reiterated H.C. Wainwright
Buy
$229 → $310
Oct-06-20 Initiated Barclays
Overweight
$156
Mar-24-20 Downgrade Argus
Buy → Hold
Mar-10-20 Initiated Guggenheim
Neutral
Feb-06-20 Initiated The Benchmark Company
Buy
$135
Sep-19-19 Upgrade Barclays
Equal Weight → Overweight
$110 → $132
Jun-11-19 Initiated Barclays
Equal Weight
$131
May-03-19 Reiterated H.C. Wainwright
Buy
$254 → $214
Mar-06-19 Reiterated H.C. Wainwright
Buy
$281 → $254
Oct-29-18 Upgrade ROTH Capital
Neutral → Buy
Oct-02-18 Reiterated H.C. Wainwright
Buy
$270 → $280
Sep-11-18 Reiterated Argus
Buy
$260 → $300
Aug-17-18 Initiated Goldman
Neutral
$256
Aug-08-18 Downgrade ROTH Capital
Buy → Neutral
Jun-21-18 Initiated Argus
Buy
$260
Dec-27-17 Reiterated H.C. Wainwright
Buy
$163 → $169
Sep-05-17 Resumed H.C. Wainwright
Buy
$150
Oct-05-16 Reiterated H.C. Wainwright
Buy
$146 → $160
Aug-05-16 Downgrade Deutsche Bank
Hold → Sell
$104 → $110
Show Previous Ratings
May-23-24 04:59PM
May-20-24 06:00AM
May-13-24 12:00PM
May-10-24 08:50AM
May-09-24 09:40AM
01:22PM
Loading…
May-08-24 01:22PM
12:19PM
May-07-24 09:01PM
05:40PM
04:00PM
11:29AM
07:30AM
Apr-23-24 08:31AM
Apr-17-24 09:55AM
Apr-08-24 08:15AM
06:00PM
Loading…
Apr-05-24 06:00PM
Apr-04-24 09:30AM
09:00AM
Apr-03-24 09:00AM
Apr-01-24 06:15PM
Mar-28-24 11:30AM
Mar-26-24 06:15PM
Mar-21-24 09:00AM
Mar-20-24 06:00PM
Mar-19-24 09:30AM
Mar-14-24 06:00PM
Mar-07-24 09:00AM
Mar-05-24 04:01PM
Mar-04-24 08:00AM
Feb-29-24 09:30AM
07:34AM
Loading…
Feb-28-24 07:34AM
Feb-27-24 07:00AM
Feb-22-24 04:01PM
Feb-16-24 08:00AM
Feb-13-24 04:01PM
Feb-01-24 05:00PM
Jan-10-24 07:30PM
Jan-05-24 04:30PM
Dec-12-23 12:01PM
09:00AM
09:00AM
Dec-11-23 09:00AM
Dec-06-23 04:02PM
Dec-01-23 08:20AM
Nov-28-23 09:01AM
Nov-09-23 04:47PM
Nov-08-23 04:01PM
Nov-06-23 09:00AM
Nov-01-23 08:00AM
Oct-25-23 04:01PM
Oct-18-23 08:00AM
Oct-09-23 06:15PM
Oct-03-23 06:00PM
Oct-02-23 09:00AM
09:00AM
Sep-27-23 09:00AM
Sep-26-23 05:05PM
Sep-22-23 09:00AM
Sep-21-23 09:20AM
Sep-18-23 05:17PM
Sep-01-23 10:02PM
Aug-08-23 04:01PM
Jul-27-23 01:30PM
Jul-25-23 04:30PM
Jul-17-23 08:59AM
08:45AM
Jun-29-23 09:00AM
Jun-21-23 08:00PM
Jun-09-23 09:40AM
Jun-06-23 11:40AM
11:10AM
Jun-05-23 11:49AM
09:01AM
Jun-02-23 12:39PM
12:35PM
Jun-01-23 11:29AM
May-30-23 07:01PM
May-25-23 05:00PM
May-24-23 09:55AM
09:40AM
May-17-23 01:59PM
08:07AM
May-16-23 09:56AM
07:30AM
07:00AM
May-12-23 12:08PM
11:34AM
May-11-23 12:25PM
May-08-23 12:32PM
09:55AM
May-06-23 10:13AM
May-05-23 10:00AM
May-04-23 05:45PM
04:01PM
06:26AM
May-02-23 08:30PM
12:06PM
11:40AM
Apr-28-23 02:04PM
Apr-27-23 09:04AM
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Espinoza Octavio Chief Financial Officer May 17 '24 Option Exercise 55.71 6,917 385,346 28,535 May 17 07:59 PM Espinoza Octavio Chief Financial Officer May 17 '24 Sale 86.66 5,156 446,844 23,379 May 17 07:59 PM Espinoza Octavio Chief Financial Officer May 16 '24 Sale 86.00 2,264 194,712 21,618 May 17 07:59 PM Espinoza Octavio Chief Financial Officer May 15 '24 Sale 86.01 5,873 505,148 23,882 May 17 07:59 PM Korenberg Matthew E President & Chief Operating May 14 '24 Sale 85.10 14,158 1,204,912 86,263 May 15 07:34 PM Korenberg Matthew E President & Chief Operating May 13 '24 Sale 84.54 3,440 290,828 100,421 May 15 07:34 PM Reardon Andrew Chief Legal Officer & May 09 '24 Option Exercise 52.27 10,000 522,700 32,205 May 13 05:32 PM Reardon Andrew Chief Legal Officer & May 09 '24 Sale 83.04 10,000 830,449 22,205 May 13 05:32 PM Gray Nancy Ryan Director May 09 '24 Sale 83.20 934 77,713 5,633 May 17 08:00 PM Aryeh Jason Director Apr 30 '24 Option Exercise 52.30 2,406 125,834 76,828 May 02 06:07 PM KOZARICH JOHN W Director Apr 24 '24 Option Exercise 39.35 2,893 113,840 42,523 Apr 26 06:35 PM Davis Todd C Chief Executive Officer Mar 25 '24 Option Exercise 57.39 16,015 919,147 120,160 Mar 27 05:47 PM Aryeh Jason Director Mar 05 '24 Option Exercise 39.35 2,893 113,840 74,422 Mar 06 05:28 PM Sabba Stephen L Director Mar 05 '24 Option Exercise 0.00 2,893 0 30,819 Mar 07 01:27 PM Sabba Stephen L Director Mar 05 '24 Sale 74.30 1,893 140,650 28,926 Mar 07 01:27 PM Espinoza Octavio Chief Financial Officer Feb 28 '24 Option Exercise 56.62 1,264 71,564 29,895 Feb 29 06:50 PM Espinoza Octavio Chief Financial Officer Feb 28 '24 Sale 88.46 140 12,384 29,755 Feb 29 06:50 PM Davis Todd C CHIEF EXECUTIVE OFFICER Sep 22 '23 Buy 59.38 4,000 237,529 73,090 Sep 25 04:44 PM
Index RUT P/E - EPS (ttm) -0.93 Insider Own 7.11% Shs Outstand 110.27M Perf Week -6.34%
Market Cap 6.92B Forward P/E - EPS next Y -1.54 Insider Trans -9.80% Shs Float 102.43M Perf Month -8.87%
Income -93.72M PEG - EPS next Q -0.27 Inst Own 72.81% Short Float 11.89% Perf Quarter 63.07%
Sales 0.00M P/S - EPS this Y -21.98% Inst Trans -0.29% Short Ratio 1.94 Perf Half Y 442.82%
Book/sh 8.47 P/B 7.41 EPS next Y -38.65% ROA -16.76% Short Interest 12.17M Perf Year 187.05%
Cash/sh 8.73 P/C 7.19 EPS next 5Y 40.00% ROE -17.55% 52W Range 8.28 - 99.41 Perf YTD 237.18%
Dividend Est. - P/FCF - EPS past 5Y -18.89% ROI -10.03% 52W High -36.88% Beta 1.04
Dividend TTM - Quick Ratio 29.48 Sales past 5Y 0.00% Gross Margin - 52W Low 657.85% ATR (14) 4.52
Dividend Ex-Date - Current Ratio 29.48 EPS Y/Y TTM 0.82% Oper. Margin 0.00% RSI (14) 38.32 Volatility 4.90% 6.51%
Employees 27 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 112.35
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -6.06% Payout - Rel Volume 0.34 Prev Close 61.57
Sales Surprise - EPS Surprise 6.04% Sales Q/Q - Earnings Apr 24 AMC Avg Volume 6.27M Price 62.75
SMA20 -14.35% SMA50 -12.49% SMA200 83.04% Trades
Volume 2,117,969 Change 1.92%
Date
Action
Analyst
Rating Change
Price Target Change
May-16-24 Upgrade Raymond James
Outperform → Strong Buy
$115 → $116
Mar-26-24 Reiterated Oppenheimer
Outperform
$116 → $138
Mar-07-24 Initiated Jefferies
Buy
$110
Feb-28-24 Reiterated Oppenheimer
Outperform
$46 → $116
May-31-23 Resumed ROTH MKM
Buy
$32
Mar-28-23 Reiterated Maxim Group
Buy
$15 → $25
Mar-17-23 Initiated Stifel
Buy
$22
Jul-29-21 Resumed BTIG Research
Buy
$20
May-25-21 Downgrade Raymond James
Strong Buy → Outperform
$27 → $12
Jun-05-20 Initiated BMO Capital Markets
Outperform
$14
May-05-20 Initiated Chardan Capital Markets
Buy
$15
May-01-20 Initiated BTIG Research
Buy
$9
Jul-16-19 Initiated Oppenheimer
Outperform
$12
Jun-25-19 Initiated Stifel
Buy
Mar-29-19 Upgrade SVB Leerink
Mkt Perform → Outperform
$10 → $21
Mar-14-19 Reiterated Maxim Group
Buy
$28 → $20
Feb-22-19 Initiated SVB Leerink
Mkt Perform
Dec-12-18 Initiated B. Riley FBR
Buy
$16
Nov-19-18 Upgrade Raymond James
Outperform → Strong Buy
Sep-18-18 Reiterated Raymond James
Outperform
$15 → $43
Show Previous Ratings
May-26-24 08:31AM
May-25-24 12:00PM
08:15AM
May-24-24 06:30AM
May-23-24 06:00AM
08:15AM
Loading…
May-22-24 08:15AM
07:07AM
May-21-24 02:36PM
May-20-24 07:02AM
May-18-24 06:47AM
May-17-24 03:02PM
09:00AM
07:30AM
06:15AM
May-16-24 07:00AM
11:36AM
Loading…
May-15-24 11:36AM
May-14-24 07:08AM
May-13-24 10:00AM
08:15AM
May-10-24 06:55AM
May-09-24 10:34AM
May-08-24 01:22PM
May-07-24 02:04PM
May-06-24 03:10AM
May-03-24 03:05AM
May-02-24 06:49PM
May-01-24 11:59AM
Apr-28-24 10:30AM
09:07AM
Apr-26-24 08:15AM
06:00AM
Loading…
06:00AM
Apr-25-24 11:28AM
10:30AM
09:01AM
07:37AM
(Thomson Reuters StreetEvents)
03:20AM
Apr-24-24 08:57PM
05:37PM
05:32PM
04:05PM
05:50AM
Apr-23-24 09:15AM
Apr-22-24 06:00AM
Apr-19-24 05:45PM
11:16AM
Apr-17-24 04:05PM
Apr-16-24 01:19PM
Apr-13-24 08:47AM
Apr-12-24 06:25AM
Apr-11-24 01:49PM
12:24PM
Apr-10-24 05:45PM
08:59AM
Apr-09-24 10:00AM
06:45AM
Apr-08-24 05:55AM
Apr-06-24 08:47PM
07:45AM
Apr-05-24 07:15AM
Apr-04-24 09:15AM
06:30AM
05:50AM
04:55AM
Apr-02-24 05:50AM
Apr-01-24 01:49PM
Mar-31-24 10:15PM
09:31AM
06:15AM
Mar-29-24 09:15AM
09:00AM
08:51AM
Mar-28-24 01:50PM
10:52AM
(Investor's Business Daily)
05:50AM
Mar-27-24 12:42PM
12:22PM
(Investor's Business Daily)
Mar-26-24 04:15PM
(Investor's Business Daily) +16.82%
01:25PM
01:02PM
12:59PM
11:58AM
11:28AM
11:17AM
11:15AM
11:13AM
10:57AM
10:07AM
08:06AM
07:12AM
07:09AM
07:03AM
05:51AM
04:11AM
Mar-25-24 06:25AM
Mar-24-24 09:15AM
Mar-23-24 05:53AM
Mar-22-24 04:55AM
Mar-21-24 08:49AM
Mar-20-24 08:30AM
08:00AM
(Investor's Business Daily)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ZANTE GREG Chief Financial Officer May 03 '24 Option Exercise 4.86 34,249 166,285 241,610 May 03 08:51 PM ZANTE GREG Chief Financial Officer May 03 '24 Sale 74.69 66,756 4,986,008 174,854 May 03 08:51 PM Mancini Marianna Chief Operating Officer May 01 '24 Option Exercise 6.18 281,425 1,740,575 629,933 May 02 09:27 PM Mancini Marianna Chief Operating Officer May 01 '24 Sale 78.66 281,425 22,136,474 348,508 May 02 09:27 PM Lian Brian President & CEO Feb 09 '24 Sale 29.90 45,000 1,345,500 2,139,882 Feb 09 08:59 PM Lian Brian President & CEO Feb 08 '24 Option Exercise 3.76 189,079 711,367 2,404,882 Feb 08 07:40 PM Rouan Sarah Kathryn Director Feb 08 '24 Option Exercise 8.32 25,000 208,000 25,000 Feb 08 07:38 PM Lian Brian President & CEO Feb 08 '24 Sale 26.87 269,079 7,230,784 2,184,882 Feb 08 07:40 PM Rouan Sarah Kathryn Director Feb 08 '24 Sale 28.05 25,000 701,250 0 Feb 08 07:38 PM Lian Brian President & CEO Jan 31 '24 Option Exercise 1.23 85,000 104,550 2,349,882 Jan 31 08:39 PM Lian Brian President & CEO Jan 31 '24 Sale 24.71 85,000 2,100,750 2,264,882 Jan 31 08:39 PM Lian Brian President & CEO Jan 30 '24 Option Exercise 1.23 35,000 43,050 2,299,882 Jan 30 09:05 PM Lian Brian President & CEO Jan 30 '24 Sale 23.95 35,000 838,250 2,264,882 Jan 30 09:05 PM Rouan Sarah Kathryn Director Jan 19 '24 Option Exercise 8.32 30,000 249,600 30,000 Jan 19 08:35 PM Rouan Sarah Kathryn Director Jan 19 '24 Sale 23.05 30,000 691,500 0 Jan 19 08:35 PM ZANTE GREG Chief Financial Officer Jan 04 '24 Sale 17.90 15,000 268,500 180,730 Jan 04 09:35 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
